Pharm5

Pharm5

By Elizabeth B. Hearn, PharmD, BCACPMedicineHealth & Fitness
Download on the App Store

Pharm5 episodes

  • OTC Narcan, PBM Transparency Act, rocuronium shortage, & more!

    This week on Pharm5:

    • Narcan possibly OTC soon
    • Dexcom G7 now available
    • PBM Transparency Act hearing
    • Rocuronium shortage
    • Phase I Rankings now open


      • Connect with us!

      • Listen to our podcast: Pharm5
      • Follow us on Twitter: @LizHearnPharmD


        • References:

        1. Hoffman J. Narcan is safe to sell over the counter, advisers to the F.D.A. conclude. The New York Times. http://bit.ly/3S2btPf. Published February 15, 2023. Accessed February 16, 2023.
        2. Person, Bhanvi Satija PJ. U.S. FDA panel backs OTC opioid overdose drug, proposes label changes. Reuters. http://bit.ly/3xrx0r5. Published February 16, 2023. Accessed February 16, 2023.
        3. New Dexcom G7 CGM Nick Jonas Super bowl 2023. Dexcom. http://bit.ly/3Is32cU. Accessed February 16, 2023.
        4. Dexcom G7 receives FDA clearance: The most accurate continuous glucose monitoring system cleared in the U.S. Business Wire. https://bit.ly/3UMwMnv. Published December 8, 2022. Accessed February 16, 2022.
        5. Bringing transparency and accountability to Pharmacy Benefit Managers. U.S. Senate Committee on Commerce, Science, & Transportation. http://bit.ly/3YAhjKg. Published February 16, 2023. Accessed February 16, 2023.
        6. FDA drug shortages. FDA Drug Shortages. http://bit.ly/3Ir1kZb. Accessed February 16, 2023.
        7. Drug shortage detail: Rocuronium injection. ASHP. http://bit.ly/3Kat9q3. Accessed February 16, 2023.
        8. Schedule of dates. ASHP Match | Schedule. http://bit.ly/3I8MJA7. Published January 19, 2023. Accessed February 16, 2023.
          9. 5 min
        9. 2023 Immunization Schedules, NAPLEX/MPJE pass rates, and more!

          This week on Pharm5:

          • Adult Immunization Schedule 2023
          • Pediatric Immunization Schedule 2023
          • Rapid acting antidepressant, Zuranolone
          • 2022 NAPLEX/MPJE Pass Rates
          • State of the Union Address


            • Connect with us!

            • Listen to our podcast: Pharm5
            • Follow us on Twitter: @LizHearnPharmD


              • References:

              1. Murthy N, Wodi AP, Cineas S, Ault KA. Recommended Adult Immunization Schedule, United States, 2023. https://doi.org/10.7326/M23-0041. Ann Int Med. 2023.
              2. The 5 biggest changes in the 2023 adult vaccine schedules. Medscape. http://bit.ly/40WmmX5. Published February 9, 2023. Accessed February 9, 2023.
              3. Committee on Infectious Diseases. Recommended Childhood and Adolescent Immunization Schedule: United States, 2023. https://doi.org/10.1542/peds.2022-061029. Pediatrics. 2023.
              4. Swift D. AAP approves 2023 Child and adolescent immunization schedule. Medscape. http://bit.ly/3RMFhPD. Published February 9, 2023. Accessed February 9, 2023.
              5. Biogen and Sage Therapeutics announce FDA accepts filing of New Drug Application and grants priority review of Zuranolone in the treatment of major depressive disorder and postpartum depression. Biogen. http://bit.ly/3HR6pbB. Accessed February 9, 2023.
              6. Data & Research. National Association of Boards of Pharmacy. http://bit.ly/40W5qQv. Accessed February 9, 2023.
              7. Aislinn Antrim E. State of the union address focuses on affordable health care, cost of insulin. Pharmacy Times. http://bit.ly/3jPc4qT. Published February 8, 2023. Accessed February 9, 2023.
              8. Full 2023 President Biden State of the Union Annotated and fact checked. CNN. http://bit.ly/3YlJs7w. Accessed February 9, 2023.
                9. 5 min
              9. "Pharmacist shortage," GoodRx in hot water, COVID updates, and more!

                This week on Pharm5:

                • Walmart, CVS Claim Pharmacist Shortage
                • Changes to Paxlovid, Lagevrio, and COVID vaccines
                • EzriCare eyedrops linked to bacterial outbreak
                • New FDA approvals: Jayprica, Orserdu, Jesduvroq
                • GoodRx sells health info to advertisers


                  • Connect with us!

                  • Listen to our podcast: Pharm5
                  • Follow us on Twitter: @LizHearnPharmD


                    • References:

                    1. Valinsky J. CVS and Walmart Cut Pharmacy Hours, close some locations earlier, citing staffing shortage | CNN business. CNN. http://bit.ly/3RpgS2F. Published January 27, 2023. Accessed February 2, 2023.
                    2. Keagy J. American Pharmacists Association on move to cut pharmacy hours. American Pharmacists Association. http://bit.ly/3JB0v0Q. Published January 30, 2023. Accessed February 2, 2023.
                    3. Paxlovid, Lagevrio prescriptions no longer need a positive COVID-19 test. Becker's Hospital Review. http://bit.ly/3DC3Jh3. Published February 1, 2023. Accessed February 2, 2023.
                    4. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. New York, NY: Pfizer. https://bit.ly/3RvXNvO. Revised February 1, 2023. Accessed February 2, 2023.
                    5. Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules). Rahway, NJ: Merck & Co. https://bit.ly/3HsLo72. Revised February 1, 2023. Accessed February 2, 2023.
                    6. Bulloch M. FDA Advisory Committee vote to simplify covid-19 regimen. Pharmacy Times. http://bit.ly/3jweY3t. Published February 1, 2023. Accessed February 2, 2023.
                    7. O'Mary L. Bacterial outbreak linked to EzriCare eyedrops: CDC. Medscape. http://bit.ly/3l3tOz9. Published February 1, 2023. Accessed February 2, 2023.
                    8. Update: Multistate Cluster of VIM- and GES-producing Carbapenem resistant Pseudomonas aeruginosa associated with Artificial Tears. https://bit.ly/3DDHrey. Published January 20, 2023. Accessed February 2, 2023.
                    9. Center for Drug Evaluation and Research. Novel drug approvals for 2023. U.S. Food and Drug Administration. http://bit.ly/3wO6ckC. Accessed February 2, 2023.
                    10. Pagliarulo N. FDA approves cancer drugs from Lilly, Menarini. BioPharma Dive. http://bit.ly/3DEgnfc. Published January 30, 2023. Accessed February 2, 2023.
                    11. FDA approves first oral treatment for anemia caused by chronic kidney disease for adults on dialysis. U.S. Food and Drug Administration. http://bit.ly/3RsL64E. Accessed February 2, 2023.
                    12. FTC enforcement action to Bar Goodrx from sharing consumers' sensitive health info for advertising. Federal Trade Commission. http://bit.ly/3l50F6C. Published February 1, 2023. Accessed February 2, 2023.
                      13. 5 min
                    13. Amazon's RxPass, Omicron XBB, TidePool Loop, and more!

                      This week on Pharm5:

                      • Amazon’s RxPass Subscription
                      • Brenzavy (bexagliflozin) for T2DM
                      • Leqimbi (lecanemab) for mild Alzheimer disease
                      • Vaccine efficacy for Omicron XBB
                      • TidePool Loop app cleared by FDA


                        • Connect with us!

                        • Listen to our podcast: Pharm5
                        • Follow us on Twitter: @LizHearnPharmD


                          • References:

                          1. Gupta V. Introducing RxPass from Amazon Pharmacy, a $5 prescription subscription that helps prime members who take multiple medications save time and money. US About Amazon. http://bit.ly/3ReGKhE. Published January 24, 2023. Accessed January 26, 2023.
                          2. All RxPass medications. http://bit.ly/3kN8628. Accessed January 27, 2023.
                          3. FDA grants accelerated approval for Alzheimer's disease treatment. U.S. Food and Drug Administration. http://bit.ly/3HxSkRI. Accessed January 26, 2023.
                          4. Lecanemab. Lexi-Drugs. Hudson, OH: Lexicomp, 2015. http://bit.ly/3DeqR4X. Accessed January 26, 2023.
                          5. Park B. Brenzavvy approved for adults with type 2 diabetes. MPR. http://bit.ly/3DjPME3. Published January 23, 2023. Accessed January 26, 2023.
                          6. Early estimates of bivalent mrna booster dose vaccine effectiveness in preventing symptomatic SARS-COV-2 infection attributable to omicron ba.5– and XBB/XBB.1.5–related sublineages among immunocompetent adults - increasing community access to testing program, United States, December 2022–January 2023. Centers for Disease Control and Prevention. https://bit.ly/3kRkMos. Published January 25, 2023. Accessed January 26, 2023.
                          7. NCIRD Surveillance Systems. Centers for Disease Control and Prevention. https://bit.ly/3wzcfti.  Published January 17, 2023. Accessed January 26, 2023.
                          8. Groundbreaking: Tidepool Loop receives FDA clearance. Tidepool. http://bit.ly/3kFRtoR. Accessed January 26, 2023.
                          9. Briskin A. Tidepool Loop cleared by FDA. diaTribe. https://bit.ly/3XH2mFL. Published January 26, 2023. Accessed January 26, 2023.
                            10. 5 min
                          10. Glaspie v. NABP, chlorthalidone v. HCTZ, the end of federal COVID-19 funding, and more!

                            Thanks to members of Phi Delta Chi's Delta Beta Chapter for creating this episode - Angelica Okinda, Nihitha Nukala, Shannyn Gilchrist-Oates, Hunter Kieltyka, Sydney Thompson, Dylan J. McNutt, Kristopher S. Ingram, Rebecca Nelson, and Emmanuel Rodivera!


                            This week on Pharm5:

                            • Glaspie v. NABP
                            • Chlorthalidone not superior to HCTZ
                            • Krazati (adagrasib) FDA approval
                            • ASHP reports 20 states prescribing OCP
                            • Federal COVID-19 vaccine funding ends


                              • Connect with us!

                              • Listen to our podcast: Pharm5
                              • Follow us on Twitter: @LizHearnPharmD


                                • References:

                                1. Ludens ZD, Glaspie E. In the United States District Court for the Northern District of Illinois. Class Action. https://bit.ly/3V7VhM5. Published November 19, 2022. Accessed December 15, 2022.
                                2. @NABP. As you may have heard, 220 candidates who took the NAPLEX between July 30th and October 26th received incorrect exam results. https://bit.ly/3UXHfN3. Posted November 10, 2022. Accessed December 15, 2022.
                                3. Ishani A, Leatherman SM, Woods P, et al. Design of a pragmatic clinical trial embedded in the Electronic Health Record: The VA's diuretic comparison project. Contemporary Clinical Trials. 2022;116:106754. doi:10.1016/j.cct.2022.106754
                                4. Flack JM, Sica DA, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as the preferred diuretic. Hypertension. 2011;57(4):665-666. doi:10.1161/hypertensionaha.110.164566
                                5. Ishani A, Cushman WC, Leatherman SM, Lew RA, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events. 10.1056/NEJMoa2212270.
                                6. FDA grants accelerated approval to Adagrasib for Kras-G12C-mutated NSCLC. Pharmacy Times. https://bit.ly/3YvCRI8. Published December 13, 2022. Accessed December 15, 2022.
                                7. Pharmacists can now prescribe hormonal birth control in 20 states. https://bit.ly/3HGMYUI. Published December 5, 2022. Accessed December 15, 2022.
                                8. Contraception. Centers for Disease Control and Prevention. https://bit.ly/3BGTRl7. Published November 1, 2022. Accessed December 15, 2022.
                                9. Pharmacist prescribing: Hormonal contraceptives. https://bit.ly/3hqbHSx. Published December 6, 2022. Accessed December 15, 2022.
                                10. Stephenson J. US COVID-19 Vaccine Costs Expected to Soar if Funding for Federal Program Ends. JAMA Health Forum. 2022;3(12):e225376. doi:10.1001/jamahealthforum.2022.5376
                                11. Artiga S, Tolbert J, Kates J, Rudowitz R. Implications of the lapse in federal covid-19 funding on access to covid-19 testing, treatment, and vaccines. KFF. bit.ly/3FWDLpM. Published March 28, 2022. Accessed December 15, 2022.
                                  12. 5 min
                                12. COVID and monkeypox vaccines, PCAT retirement, and new FDA approvals!

                                  This week on Pharm5:

                                  • Bivalent booster for kids
                                  • Jynneos protects against monkeypox
                                  • Dexcom G7 approved for diabetes
                                  • Rezlidhia (olutasidenib) approved for AML
                                  • PCAT retirement in 2024


                                    • Connect with us!

                                    • Listen to our podcast: Pharm5
                                    • Follow us on Twitter: @LizHearnPharmD


                                      • References:

                                      1. Coronavirus (COVID-19) update: FDA authorizes updated (bivalent) covid-19 vaccines for children down to 6 months of age. U.S. Food and Drug Administration. https://bit.ly/3UIOuIP. Accessed December 8, 2022.
                                      2. Webinar November 29, 2022 - flu, RSV, COVID-19 and other respiratory threats this fall and Winter. Centers for Disease Control and Prevention. http://bit.ly/3Bf21AX. Published November 16, 2022. Accessed December 8, 2022.
                                      3. Reduced risk for Mpox after receipt of 1 or 2 doses of JYNNEOS vaccine compared with risk among unvaccinated persons - 43 U.S. jurisdictions, July 31–October 1, 2022. Centers for Disease Control and Prevention. https://bit.ly/3FzvTdL. Published December 8, 2022. Accessed December 8, 2022.
                                      4. Dexcom G7 receives FDA clearance: The most accurate continuous glucose monitoring system cleared in the U.S. Business Wire. https://bit.ly/3UMwMnv. Published December 8, 2022. Accessed December 8, 2022.
                                      5. Center for Drug Evaluation and Research. FDA approves Olutasidenib. U.S. Food and Drug Administration. https://bit.ly/3W2vSo5. Accessed December 8, 2022.
                                      6. Pharmcas Community. Retirement of the Pharmacy College Admission Test (PCAT). https://bit.ly/3Y9EomW. Published December 6, 2022. Accessed December 8, 2022.
                                        7. 5 min
                                      7. Tamiflu availability, ADHD medications & CVD, no more mAbs for COVID, and more!

                                        This week on Pharm5:

                                        • Tamiflu backorder
                                        • ADHD medications & CVD risk
                                        • Paxlovid dispensing guidance
                                        • EUA pulled for last remaining COVID-19 monoclonal antibody
                                        • ASHP Midyear Meeting


                                          • Connect with us!

                                          • Listen to our podcast: Pharm5
                                          • Follow us on Twitter: @LizHearnPharmD


                                            • References:

                                            1. Current drug shortages. ASHP. https://bit.ly/3Fk0Keo. Accessed December 1, 2022.
                                            2. Center for Drug Evaluation and Research. Drug shortages. U.S. Food and Drug Administration. https://bit.ly/3B2DGhC. Accessed December 1, 2022.
                                            3. Weekly U.S. Influenza Surveillance Report. Centers for Disease Control and Prevention. https://bit.ly/3gQ77MW. Published November 28, 2022. Accessed December 1, 2022.
                                            4. Zhang L, Yao H, Li L, et al. Risk of cardiovascular diseases associated with medications used in attention-deficit/hyperactivity disorder. JAMA Network Open. 2022;5(11). doi:10.1001/jamanetworkopen.2022.43597
                                            5. HQ APhA. APhA has created a pharmacist decision-making support tool for paxlovid. use it in your practices to help assess whether a prescription for Paxlovid is appropriate. Twitter. https://bit.ly/3H6F3Q7. Published November 30, 2022. Accessed December 1, 2022.
                                            6. FDA pulls U.S. authorization for Eli Lilly's Covid Drug Bebtelovimab. Reuters. https://bit.ly/3UiQyHa. Published November 30, 2022. Accessed December 1, 2022.
                                            7. Midyear clinical meeting 2022 - ASHP. MCM22. https://bit.ly/3B1dunI. Accessed December 1, 2022.
                                              8. 4 min
                                            8. T1DM prevention, OTC naloxone, pharmacogenomic testing, and more!

                                              This week on Pharm5:

                                              • BCEMP starting in 2023
                                              • FDA hints at OTC naloxone
                                              • Elahere for advanced ovarian cancer
                                              • Pharmacogenomics reduces risk of ADRs
                                              • Tzield delays T1DM symptom onset


                                                • Connect with us!

                                                • Listen to our podcast: Pharm5
                                                • Follow us on Twitter: @LizHearnPharmD


                                                  • References:

                                                  1. Jean-Baptiste A. First Administration of the emergency medicine pharmacy certification examination announced for 2023. Board of Pharmacy Specialties. http://bit.ly/3EeGIQx.  Published November 10, 2022. Accessed November 17, 2022.
                                                  2. The Federal Register. Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription Use; Request for Comments. http://bit.ly/3tGEQLu. Published November 16, 2022. Accessed November 17, 2022.
                                                  3. Pharmacy Practice News. http://bit.ly/3EepDq5. Published November 16, 2022. Accessed November 16, 2022.
                                                  4. Dunleavy K. Four decades in, immunogen gets landmark green light in Advanced ovarian cancer. Fierce Pharma. http://bit.ly/3Ao8Hw9. Published November 15, 2022. Accessed November 17, 2022.
                                                  5. Immunogen announces FDA accelerated approval of ELAHERE™ (Mirvetuximab Soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer. ImmunoGen, Inc. http://bit.ly/3gjvHp5.  Accessed November 17, 2022.
                                                  6. Robinson J. Adverse drug reactions reduced by nearly one third after genetic testing, major trial results to show. The Pharmaceutical Journal. http://bit.ly/3TQK1TQ. Published November 14, 2022. Accessed November 17, 2022.
                                                  7. FDA approves first drug that can delay onset of type 1 diabetes. U.S. Food and Drug Administration. http://bit.ly/3gd9j0G. Published November 17, 2022. Accessed November 17, 2022.
                                                    8. 5 min
                                                  8. NAPLEX scoring error, 2022 flu season updates, opioid tapering guidance, and more!

                                                    This week on Pharm5:

                                                    • CDC Opioid Prescribing and Tapering Guidance
                                                    • NAPLEX Scoring Errors from NABP
                                                    • Third COVID vax is helpful, fourth is not
                                                    • USPSTF Recommendations for Hormone Use
                                                    • 2022 Flu Season Hitting Early


                                                      • Connect with us!

                                                      • Listen to our podcast: Pharm5
                                                      • Follow us on Twitter: @LizHearnPharmD


                                                        • References:

                                                        1. CDC Clinical Practice Guideline for prescribing opioids for pain - united states, 2022. Centers for Disease Control and Prevention. http://bit.ly/3Ej7Ejv. Published November 3, 2022. Accessed November 9, 2022.
                                                        2. Brooks M. New CDC guidance on prescribing opioids for pain. Medscape. http://bit.ly/3EeuLKX.  Published November 4, 2022. Accessed November 9, 2022.
                                                        3. @NABP. Posted November 10, 2022. Accessed November 10, 2022. https://twitter.com/nabp/status/1590809815156137995.
                                                        4. Canetti M, Barda N, Gilboa M, et al. Six-month follow-up after a fourth BNT162b2 vaccine dose. New England Journal of Medicine. November 2022. doi:10.1056/nejmc2211283
                                                        5. Chalkias S, Harper C, Vrbicky K, et al. A bivalent omicron-containing booster vaccine against covid-19. New England Journal of Medicine. 2022;387(14):1279-1291. doi:10.1056/nejmoa2208343
                                                        6. Hormone therapy in postmenopausal persons: Primary prevention of chronic conditions. Recommendation: Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce. http://bit.ly/3NY7Tnh.  Published November 1, 2022. Accessed November 10, 2022.
                                                        7. Weekly U.S. Influenza Surveillance Report. Centers for Disease Control and Prevention. http://bit.ly/3TshBiV. Published November 10, 2022. Accessed November 10, 2022.
                                                        8. Influenza activity and composition of the 2022–23 influenza vaccine - United States, 2021–22 season. Centers for Disease Control and Prevention. http://bit.ly/3DWJgTi. Published July 21, 2022. Accessed November 10, 2022.
                                                          9. 4 min
                                                        9. Virtual Residency Showcase, psilocybin results, Walgreens removes speed metrics, and more!

                                                          This week on Pharm5:

                                                          • SNPhA x ACCP Residency Showcase
                                                          • Amoxicillin suspension shortage
                                                          • Psilocybin for episodes of major depression
                                                          • RSV vaccine trials
                                                          • Walgreens removes speed metrics


                                                            • Connect with us!

                                                            • Listen to our podcast: Pharm5
                                                            • Follow us on Twitter: @LizHearnPharmD


                                                              • References:

                                                              1. SNPhA x ACCP Residency and Fellowship Showcase. ACCP. https://bit.ly/3fyqSrQ. Accessed November 3, 2022.
                                                              2. Weixel N. FDA reports shortages of amoxicillin. The Hill. https://bit.ly/3fsEODL. Published November 1, 2022. Accessed November 3, 2022.
                                                              3. Amoxil. Package Insert. GlaxoSmithKline; 2006.
                                                              4. FDA drug shortages. FDA Drug Shortages. https://bit.ly/3UlvAb5. Accessed November 3, 2022.
                                                              5. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of Major Depression. New England Journal of Medicine. 2022;387(18):1637-1648. doi:10.1056/nejmoa2206443
                                                              6. RSV vaccine protects babies from severe infections, Pfizer study finds. The Wall Street Journal. https://on.wsj.com/3UgNAna. Published November 1, 2022. Accessed November 3, 2022.
                                                              7. Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate. https://bit.ly/3FFuh2v. Accessed November 3, 2022.
                                                              8. Walgreens sharpens focus on patient care and experience, eliminating task-based metrics for Pharmacy Staff Performance Reviews Chainwide. Walgreens Newsroom. https://bit.ly/3t1TdcU. Accessed November 3, 2022.
                                                              9. Walgreens will stop judging its pharmacy staff by how fast they work. NBCNews.com. https://nbcnews.to/3zGXvKA. Published October 28, 2022. Accessed November 3, 2022.
                                                                10. 5 min

                                                              About Pharm5

                                                              From the publisher's feed

                                                              The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.